Matsudo

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Stroke2 trials
• Atopic dermatitis (eczema)1 trial
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Chronic myeloid leukaemia1 trial
• Heart failure1 trial
• High blood pressure1 trial

Phase

• Phase 22 trials
• Phase 32 trials

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals6 trials

Running trials

• Recruiting

  Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

  NCT07830719· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

  NCT06947993· Phase 2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)1 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting

Closed trials

• Completed

  Special Drug Use Surveillance of Entresto Tablets (Hypertension)

  NCT05976230· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source